Plain-English translation of NCT06203977 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
The REPAIR trial tested whether , an anti-inflammatory medication, could help protect the heart and prevent further damage in people with severe chronic kidney disease. The trial studied two separate groups: patients with advanced kidney disease who were not yet on dialysis, and patients who were receiving regular dialysis treatments. Researchers wanted to learn how well patients tolerated the medication at two different daily doses over 8 weeks.
People with severe kidney disease face a high risk of heart problems and blood vessel damage, often driven by inflammation in the body. This trial was designed to test whether this medication could reduce that inflammation and ultimately help prevent serious heart complications in this vulnerable population.
Participants received the medication at a starting dose for the first 8 weeks, then—if they tolerated it well—the dose was increased for another 8 weeks. They were followed for up to 17 weeks total to monitor how the medication worked and whether they experienced any side effects. The trial tracked what proportion of patients were able to continue the medication at each dose level without stopping treatment.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
Canada